We are analyzing https://link.springer.com/article/10.1186/s12882-020-01888-5.

Title:
A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy | BMC Nephrology
Description:
Background Lupus nephritis (LN) is a severe consequence of systemic lupus erythematosus (SLE) that affects approximately 40% of patients. Pathogenic immune complexes that are characteristic of LN deposit in the kidney and activate immune mediated pathways including the complement system. Complete remission rates in LN are approximately 44% highlighting the need for new treatment strategies in these patients. Eculizumab is a fully humanised IgG2/IgG4 monoclonal antibody directed at C5 and thus prevents the formation of the terminal complement complex. Eculizumab is successfully used in atypical haemolytic uraemic syndrome (aHUS) and paroxysomal nocturnal haemoglobinuria (PNH) but it is not standardly used in LN. The aim of this project was to determine whether there is any role for eculizumab as adjunctive therapy in LN. Methods Using a predefined search strategy on Ovid MEDLINE and EMBASE the literature was reviewed systematically to identify studies in which eculizumab had been used to treat patients with SLE. All patients were included that were treated with complement inhibitors. Favourable outcome in this study was defined as resolution of symptoms that led to treatment, discharge from hospital or recovery of renal function. Patients were excluded if there was no outcome data or if complement inhibition was unrelated to their SLE. Results From 192 abstracts screened, 14 articles were identified, involving 30 patients. All SLE patients administered eculizumab were treated for thrombotic microangiopathy (TMA) secondary to LN diagnosed either histologically (66%) or as part of a diagnosis of aHUS (73%). 93% of patients had a favourable outcome in response to eculizumab treatment, of which 46% had a favourable outcome and successfully stopped treatment without relapse in symptoms during a median follow up of 7 months. Three patients (10%) reported adverse outcomes related to eculizumab therapy. Conclusions Scientific evidence supports the involvement of complement in the pathogenesis of LN however the role of complement inhibition in clinical practice is limited to those with TMA features. This systematic review showed that in cases of LN complicated with TMA, eculizumab seems to be a very efficacious therapy. Further evidence is required to determine whether patients with refractory LN may benefit from adjunctive complement inhibition.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

eculizumab, patients, lupus, complement, treatment, doi, sle, therapy, patient, nephritis, data, systemic, study, article, thrombotic, syndrome, disease, review, microangiopathy, outcome, tma, erythematosus, search, inhibition, role, atypical, ahus, included, systematic, haemolytic, renal, research, immune, studies, clinical, received, liverpool, access, kidney, reported, system, uraemic, secondary, response, case, health, nephrol, alder, hey, full,

Topics {✒️}

long-term observational study complement-mediated thrombotic microangiopathy microangiopathic haemolytic anaemia haemolytic uraemic syndrome full size image childhood-onset lupus nephritis antiphospholipid antibody syndrome systemic lupus erythematosus systemic lupus erythematosus �systemic lupus erythematosus” predefined search strategy method search strategy article download pdf lupus research group european evidence-based recommendations living-donor kidney transplant thrombotic microangiopathy rescues safety profile secondary thrombotic microangiopathy evidenced-based therapeutic strategies related subjects systematic review showed renal thrombotic microangiopathy privacy choices/manage cookies end-stage renal failure anti-dna antibodies full article stages membrane attack complex tma- thrombotic microangiopathy embase search engines �existent lupus nephritis active lupus nephritis alder hey charity immune complex deposition severe lupus nephritis paediatric lupus nephritis systemic literature review systemic autoimmune disease double-stranded dna systemic autoimmune condition joint european league paroxysomal nocturnal haemoglobinuria systematic literature review search terms search strategy creative commons licence remained dialysis dependent 1186/s12882-019-1314-1 immune deposits present ln- lupus nephritis

Questions {❓}

Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?
What is damaging the kidney in lupus nephritis?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
         description:Lupus nephritis (LN) is a severe consequence of systemic lupus erythematosus (SLE) that affects approximately 40% of patients. Pathogenic immune complexes that are characteristic of LN deposit in the kidney and activate immune mediated pathways including the complement system. Complete remission rates in LN are approximately 44% highlighting the need for new treatment strategies in these patients. Eculizumab is a fully humanised IgG2/IgG4 monoclonal antibody directed at C5 and thus prevents the formation of the terminal complement complex. Eculizumab is successfully used in atypical haemolytic uraemic syndrome (aHUS) and paroxysomal nocturnal haemoglobinuria (PNH) but it is not standardly used in LN. The aim of this project was to determine whether there is any role for eculizumab as adjunctive therapy in LN. Using a predefined search strategy on Ovid MEDLINE and EMBASE the literature was reviewed systematically to identify studies in which eculizumab had been used to treat patients with SLE. All patients were included that were treated with complement inhibitors. Favourable outcome in this study was defined as resolution of symptoms that led to treatment, discharge from hospital or recovery of renal function. Patients were excluded if there was no outcome data or if complement inhibition was unrelated to their SLE. From 192 abstracts screened, 14 articles were identified, involving 30 patients. All SLE patients administered eculizumab were treated for thrombotic microangiopathy (TMA) secondary to LN diagnosed either histologically (66%) or as part of a diagnosis of aHUS (73%). 93% of patients had a favourable outcome in response to eculizumab treatment, of which 46% had a favourable outcome and successfully stopped treatment without relapse in symptoms during a median follow up of 7 months. Three patients (10%) reported adverse outcomes related to eculizumab therapy. Scientific evidence supports the involvement of complement in the pathogenesis of LN however the role of complement inhibition in clinical practice is limited to those with TMA features. This systematic review showed that in cases of LN complicated with TMA, eculizumab seems to be a very efficacious therapy. Further evidence is required to determine whether patients with refractory LN may benefit from adjunctive complement inhibition.
         datePublished:2020-06-30T00:00:00Z
         dateModified:2020-06-30T00:00:00Z
         pageStart:1
         pageEnd:8
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12882-020-01888-5
         keywords:
            Lupus nephritis
            Eculizumab
            Complement
            Thrombotic microangiopathy
            Systematic review
            Nephrology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12882-020-01888-5/MediaObjects/12882_2020_1888_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12882-020-01888-5/MediaObjects/12882_2020_1888_Fig2_HTML.png
         isPartOf:
            name:BMC Nephrology
            issn:
               1471-2369
            volumeNumber:21
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Rachael D. Wright
               url:http://orcid.org/0000-0002-7606-2297
               affiliation:
                     name:University of Liverpool, member of Liverpool Health Partners
                     address:
                        name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Fariba Bannerman
               affiliation:
                     name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
                     address:
                        name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael W. Beresford
               affiliation:
                     name:University of Liverpool, member of Liverpool Health Partners
                     address:
                        name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
                        type:PostalAddress
                     type:Organization
                     name:Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
                     address:
                        name:Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Louise Oni
               affiliation:
                     name:University of Liverpool, member of Liverpool Health Partners
                     address:
                        name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
                        type:PostalAddress
                     type:Organization
                     name:Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
                     address:
                        name:Department of Paediatric Nephrology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
      description:Lupus nephritis (LN) is a severe consequence of systemic lupus erythematosus (SLE) that affects approximately 40% of patients. Pathogenic immune complexes that are characteristic of LN deposit in the kidney and activate immune mediated pathways including the complement system. Complete remission rates in LN are approximately 44% highlighting the need for new treatment strategies in these patients. Eculizumab is a fully humanised IgG2/IgG4 monoclonal antibody directed at C5 and thus prevents the formation of the terminal complement complex. Eculizumab is successfully used in atypical haemolytic uraemic syndrome (aHUS) and paroxysomal nocturnal haemoglobinuria (PNH) but it is not standardly used in LN. The aim of this project was to determine whether there is any role for eculizumab as adjunctive therapy in LN. Using a predefined search strategy on Ovid MEDLINE and EMBASE the literature was reviewed systematically to identify studies in which eculizumab had been used to treat patients with SLE. All patients were included that were treated with complement inhibitors. Favourable outcome in this study was defined as resolution of symptoms that led to treatment, discharge from hospital or recovery of renal function. Patients were excluded if there was no outcome data or if complement inhibition was unrelated to their SLE. From 192 abstracts screened, 14 articles were identified, involving 30 patients. All SLE patients administered eculizumab were treated for thrombotic microangiopathy (TMA) secondary to LN diagnosed either histologically (66%) or as part of a diagnosis of aHUS (73%). 93% of patients had a favourable outcome in response to eculizumab treatment, of which 46% had a favourable outcome and successfully stopped treatment without relapse in symptoms during a median follow up of 7 months. Three patients (10%) reported adverse outcomes related to eculizumab therapy. Scientific evidence supports the involvement of complement in the pathogenesis of LN however the role of complement inhibition in clinical practice is limited to those with TMA features. This systematic review showed that in cases of LN complicated with TMA, eculizumab seems to be a very efficacious therapy. Further evidence is required to determine whether patients with refractory LN may benefit from adjunctive complement inhibition.
      datePublished:2020-06-30T00:00:00Z
      dateModified:2020-06-30T00:00:00Z
      pageStart:1
      pageEnd:8
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12882-020-01888-5
      keywords:
         Lupus nephritis
         Eculizumab
         Complement
         Thrombotic microangiopathy
         Systematic review
         Nephrology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12882-020-01888-5/MediaObjects/12882_2020_1888_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12882-020-01888-5/MediaObjects/12882_2020_1888_Fig2_HTML.png
      isPartOf:
         name:BMC Nephrology
         issn:
            1471-2369
         volumeNumber:21
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Rachael D. Wright
            url:http://orcid.org/0000-0002-7606-2297
            affiliation:
                  name:University of Liverpool, member of Liverpool Health Partners
                  address:
                     name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Fariba Bannerman
            affiliation:
                  name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
                  address:
                     name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael W. Beresford
            affiliation:
                  name:University of Liverpool, member of Liverpool Health Partners
                  address:
                     name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
                     type:PostalAddress
                  type:Organization
                  name:Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
                  address:
                     name:Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Louise Oni
            affiliation:
                  name:University of Liverpool, member of Liverpool Health Partners
                  address:
                     name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
                     type:PostalAddress
                  type:Organization
                  name:Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
                  address:
                     name:Department of Paediatric Nephrology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Nephrology
      issn:
         1471-2369
      volumeNumber:21
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Liverpool, member of Liverpool Health Partners
      address:
         name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
         type:PostalAddress
      name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
      address:
         name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
         type:PostalAddress
      name:University of Liverpool, member of Liverpool Health Partners
      address:
         name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
         type:PostalAddress
      name:Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
      address:
         name:Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
         type:PostalAddress
      name:University of Liverpool, member of Liverpool Health Partners
      address:
         name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
         type:PostalAddress
      name:Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
      address:
         name:Department of Paediatric Nephrology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Rachael D. Wright
      url:http://orcid.org/0000-0002-7606-2297
      affiliation:
            name:University of Liverpool, member of Liverpool Health Partners
            address:
               name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Fariba Bannerman
      affiliation:
            name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
            address:
               name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
               type:PostalAddress
            type:Organization
      name:Michael W. Beresford
      affiliation:
            name:University of Liverpool, member of Liverpool Health Partners
            address:
               name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
               type:PostalAddress
            type:Organization
            name:Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
            address:
               name:Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
               type:PostalAddress
            type:Organization
      name:Louise Oni
      affiliation:
            name:University of Liverpool, member of Liverpool Health Partners
            address:
               name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
               type:PostalAddress
            type:Organization
            name:Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners
            address:
               name:Department of Paediatric Nephrology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
      name:Library and Knowledge Service, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
      name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
      name:Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK
      name:Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, member of Liverpool Health Partners, Liverpool, UK
      name:Department of Paediatric Nephrology, Alder Hey Children’s NHS Foundation Trust, member of Liverpool Health Partners, Liverpool, UK

External Links {🔗}(90)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.54s.

LINK . SPRINGER . COM {}